ÈäºÎ ´ëµ¿¸Æ·ù ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼ : Ä¡·áº°, Á¦Ç°º°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2033³â)
Thoracic Aortic Aneurysm Market Size, Share & Trends Analysis Report By Treatment (Open Surgical Repair (OSR), Thoracic Endovascular Aneurysm Repair (TEVAR)), By Product, By End Use, By Region, And Segment Forecasts, 2025 - 2033
»óǰÄÚµå
:
1813855
¸®¼Ä¡»ç
:
Grand View Research
¹ßÇàÀÏ
:
2025³â 08¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 150 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
ÈäºÎ ´ëµ¿¸Æ·ù ½ÃÀå ¿ä¾à
ÈäºÎ ´ëµ¿¸Æ·ù ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³â 16¾ï 5,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2033³â¿¡´Â 50¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2025-2033³â ¿¬Æò±Õ 13.36% ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
ÀÌ·¯ÇÑ ¼ºÀåÀÇ ¿øµ¿·ÂÀº °íÇ÷¾Ð ¹× °áÇÕÁ¶Á÷ ÁúȯÀÇ À¯º´·ü Áõ°¡, °í·ÉÈ Àα¸ Áõ°¡, Àúħ½ÀÀû Ç÷°ü³» Ä¡·áÀÇ Ã¤Åà Ȯ´ë¿¡ ±âÀÎÇÕ´Ï´Ù.
½ºÅÙÆ® ±×¶óÇÁÆ® ¼³°èÀÇ ±â¼úÀû Áøº¸, ¿µ»ó Áø´ÜÀÇ °³¼±, Áúº´ÀÇ Á¶±â ¹ß°ß µîÀÌ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. º¸Çè ±Þ¿© Á¤Ã¥ ¹× ÀÇ»ç¿Í ȯÀÚ ¸ðµÎ¿¡ ´ëÇÑ ÈäºÎ ´ëµ¿¸Æ·ù¿¡ ´ëÇÑ ÀνÄÀÌ È®´ëµÊ¿¡ µû¶ó Àü ¼¼°èÀûÀ¸·Î Ä¡·á µµÀÔÀÌ ´õ¿í °¡¼Óȵǰí ÀÖ½À´Ï´Ù.
ÈäºÎ ´ëµ¿¸Æ·ùÀÇ ÁÖ¿ä À§Çè ¿äÀÎÀÎ °íÇ÷¾Ð, Èí¿¬, µ¿¸Æ°æÈÁõÀÇ À¯º´·ü Áõ°¡´Â ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀÔ´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î °í·ÉȰ¡ ÁøÇàµÊ¿¡ µû¶ó ÅðÇ༺ Ç÷°ü ÁúȯÀÇ ¹ß»ý·üÀº °è¼Ó Áõ°¡Çϰí ÀÖÀ¸¸ç, Áø´Ü ¹× Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Á÷Á¢ÀûÀ¸·Î Áõ°¡Çϰí ÀÖ½À´Ï´Ù. 2025³â 3¿ù Biomedicines Àú³Î¿¡ °ÔÀçµÈ ³í¹®¿¡¼´Â Á׻󵿸ưæÈÁõ(AS)°ú ÈäºÎµ¿¸Æ·ù(TAA)¸¦ Æ÷ÇÔÇÑ ´ëµ¿¸Æ·ù(AA)ÀÇ °ü°è¸¦ ºÐ¼®ÇÏ¿´½À´Ï´Ù. µ¿¸Æ·ùÀÇ À§Ä¡, ³ªÀÌ, À¯ÀüÀû ¹è°æ, ÀÌ÷´ëµ¿¸ÆÆÇ¸· µîÀÇ ¿µÇâÀ» ¹Þ¾Æ µ¿¹ÝÀ²Àº 18%¿¡¼ 90%¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.
Ç÷°ü ³» µ¿¸Æ·ù Ä¡·á¼ú(TEVAR)ÀÇ ±â¼ú ¹ßÀüÀº °³º¹ ¼ö¼úÀÇ ´ë¾ÈÀ¸·Î ÃÖ¼Ò Ä§½ÀÀû ¼ö¼úÀ» Á¦°øÇÔÀ¸·Î½á ½ÃÀåÀ» Å©°Ô ¼ºÀå½ÃÄ×½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ÀÔ¿ø ±â°£ ´ÜÃà, ¼ö¼ú À§Çè °¨¼Ò, °íÀ§Ç豺 ȯÀÚ Ä¡·á ´ë»ó È®´ë µîÀ¸·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ÀÇ·á±â±â Á¦Á¶¾÷üµéÀº Á¤È®¼º, À¯¿¬¼º, ³»±¸¼ºÀ» Çâ»ó½ÃŲ Â÷¼¼´ë ½ºÅÙÆ® ±×¶óÇÁÆ®¸¦ Áö¼ÓÀûÀ¸·Î °³¹ßÇϰí ÀÖÀ¸¸ç, Àü ¼¼°è Ç÷°ü¿Ü°ú ÀÇ»çµéÀÇ Ã¤ÅÃÀ» ´õ¿í °¡¼ÓÈÇϰí ÀÖ½À´Ï´Ù. 2025³â 5¿ù, ´ÙÄ«¿¡ À§Ä¡ÇÑ SHIP ±¹Á¦º´¿øÀº ÈäºÎ ´ëµ¿¸Æ·ù(TAA)¸¦ ¾Î°í ÀÖ´Â 57¼¼ ȯÀÚ¿¡°Ô ÈäºÎ Ç÷°ü ³» ´ëµ¿¸Æ º¹¿ø¼ú(TEVAR)À» ½ÃÇàÇß½À´Ï´Ù. ´Ù¸¥ °÷¿¡¼ Ä¡·á¸¦ °ÅºÎ´çÇÑ ÈÄ NICVD ±³¼ö·ÎºÎÅÍ ¼Ò°³¹ÞÀº ÀÌ È¯ÀÚ´Â Ç÷°ü ³» ½ºÅÙÆ® ÀÌ½Ä º¥´õÀÇ Áö¿øÀ» ¹Þ¾Æ ÃÖ¼Ò Ä§½À ¼ö¼úÀ» ¹Þ¾Ò½À´Ï´Ù.
ÈäºÎ ´ëµ¿¸Æ·ù¸¦ Á¶±â¿¡ Á¤È®ÇÏ°Ô ¹ß°ßÇϱâ À§ÇØ CT, MRI, ÃÊÀ½ÆÄ µî ÷´Ü ¿µ»óÁø´Ü ±â¹ýÀÇ »ç¿ëÀÌ Áõ°¡ÇÏ¸é¼ ½ÃÀå ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. Àü±¹ÀûÀÎ °ËÁø ÇÁ·Î±×·¥°ú ÀÓ»óÀÇ¿Í È¯ÀÚ ¸ðµÎÀÇ ÀÎ½Ä °³¼±Àº Á¶±â Áø´Ü°ú Àû½Ã °³ÀÔ¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í ÇÔ²² ÀΰøÁö´É µµ±¸¿Í µðÁöÅÐ Çコ Ç÷§ÆûÀÌ Áø´Ü °æ·Î¿¡ ÅëÇÕµÇ¾î ´õ ³ªÀº À§Çè °èÃþÈ ¹× ȯÀÚ ¸ð´ÏÅ͸µÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù.
2025³â 6¿ù Nature Communications¿¡ °ÔÀçµÈ ³í¹®Àº ÀÏ»óÀûÀÎ À¯¹æ MRI ½ºÄµÀ» ÅëÇØ ÈäºÎ ´ëµ¿¸Æ·ù(TAA)ÀÇ ±âȸÁÖÀÇÀûÀÎ ½ºÅ©¸®´×À» °¡´ÉÇÏ°Ô ÇÏ´Â AI ¸ðµ¨¿¡ ´ëÇØ ³íÀÇÇß½À´Ï´Ù. ÀÌ ¸ðµ¨Àº Ç¥ÁØ ÀÓ»ó °Ë»ç¿¡ ºñÇØ °ËÃâ·üÀ» 3.5¹è Çâ»ó½ÃÄ×½À´Ï´Ù. ÀÌ ¸ðµ¨Àº ´ëµ¿¸ÆÀÇ Å©±â¿Í AHI, ASI¿Í °°Àº ü°Ý Á¶Á¤ ÁöÇ¥¸¦ ±â¹ÝÀ¸·Î °íÀ§Ç豺 ȯÀÚ¿¡°Ô Ç÷¡±×¸¦ Ç¥½ÃÇß½À´Ï´Ù.
¼¼°è ÈäºÎ ´ëµ¿¸Æ·ù ½ÃÀå ¼¼ºÐÈ
¼¼°èÀÇ ÈäºÎ ´ëµ¿¸Æ·ù(ÈäºÎ ´ëµ¿¸Æ·ù) ½ÃÀåÀ» ºÐ¼®ÇÏ¿© 2021³â-2033³â±îÁö °¢ ÇÏÀ§ ºÎ¹®ÀÇ ¼öÀÍ ¼ºÀåÀ» ¿¹ÃøÇϰí, ¼¼°è, Áö¿ª ¹× ±¹°¡º° Ãֽе¿Ç⠺м®À» Á¦°øÇÕ´Ï´Ù. ÀÌ º¸°í¼´Â ¼¼°è ÈäºÎ ´ëµ¿¸Æ·ù ½ÃÀåÀ» Ä¡·á, Á¦Ç°, ÃÖÁ¾ ¿ëµµ ¹× Áö¿ªº°·Î ºÐ·ùÇÕ´Ï´Ù.
Ä¡·á Àü¸Á(2021³â-2033³â)
°³º¹¼ö¼ú¿¡ ÀÇÇÑ ¼öº¹(OSR)
ÈäºÎ Ç÷°ü ³» µ¿¸Æ·ù Ä¡·á¼ú(TEVAR)
ºÐÁöÇü Ç÷°ü³» µ¿¸Æ·ù Ä¡·á¼ú(BEVAR)
ÇÏÀ̺긮µå ½Ã¼ú
Á¦Ç° Àü¸Á(2021³â-2033³â)
´ëµ¿¸Æ ½ºÅÙÆ® À̽Ä
´ëµ¿¸Æ ¼ö¼ú¿ë ÀÌ½ÄÆí
´ëµ¿¸Æ º¹±¸ º¸Á¶±â±¸
ÃÖÁ¾ ¿ëµµ Àü¸Á(2021³â-2033³â)
º´¿ø
¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
Áø·á¼Ò
Áö¿ªº° Àü¸Á(2021³â-2033³â)
ºÏ¹Ì
À¯·´
¿µ±¹
µ¶ÀÏ
ÇÁ¶û½º
ÀÌÅ»¸®¾Æ
½ºÆäÀÎ
µ§¸¶Å©
½º¿þµ§
³ë¸£¿þÀÌ
¾Æ½Ã¾ÆÅÂÆò¾ç
ÀϺ»
Áß±¹
Àεµ
È£ÁÖ
Çѱ¹
ű¹
¶óƾ¾Æ¸Þ¸®Ä«.
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
³²¾ÆÇÁ¸®Ä«°øÈ±¹ »ç¿ìµð¾Æ¶óºñ¾Æ ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE) Äí¿þÀÌÆ®
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå ¼¼°èÀÇ ÈäºÎ ´ëµ¿¸Æ·ù ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§
½ÃÀå °èÅë Àü¸Á
»óÀ§ ½ÃÀå Àü¸Á
º¸Á¶ ½ÃÀå Àü¸Á
½ÃÀå ¿ªÇÐ
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
¼¼°èÀÇ ÈäºÎ ´ëµ¿¸Æ·ù : ½ÃÀå ºÐ¼® Åø
¾÷°è ºÐ¼® - PorterÀÇ Five Forces ºÐ¼®
PESTLE ºÐ¼®
Ä¡·á »óȲ
»ç·Ê ¿¬±¸ ºÐ¼®
Á¦4Àå ¼¼°èÀÇ ÈäºÎ ´ëµ¿¸Æ·ù ½ÃÀå ºÎ¹® ºÐ¼®, Ä¡·á, 2021³â-2033³â
Á¤ÀÇ¿Í ¹üÀ§
Ä¡·á ½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â ¹× 2033³â
ºÎ¹® ´ë½Ãº¸µå
¼¼°èÀÇ ÈäºÎ ´ëµ¿¸Æ·ù ½ÃÀå(Ä¡·á, 2021³â-2033³â)
°³º¹ ¼ö¼ú¿¡ ÀÇÇÑ ¼öº¹(OSR)
°³º¹ ¼ö¼ú ¼öº¹(OSR) ½ÃÀå Ãß»ê ¹× ¿¹Ãø, 2021³â-2033³â
ÈäºÎ Ç÷°ü³» µ¿¸Æ·ù ¼öº¹¼ú(TEVAR)
ÈäºÎ Ç÷°ü³» µ¿¸Æ·ü ¼öº¹¼ú(TEVAR) ½ÃÀå Ãß»ê ¹× ¿¹Ãø, 2021³â-2033³â
ÇÏÀ̺긮µå ¼ö¼ú
ÇÏÀ̺긮µå ¼ö¼ú ½ÃÀå Ãß»ê ¹× ¿¹Ãø, 2021³â-2033³â
ºÐÁöÇü ³»ºÐºñ°è µ¿¸Æ·ü ³»½Ã°æ ¼ö¼ú(BEVAR)
ºÐÁöÇü ³»ºÐºñ°è µ¿¸Æ·ü ³»½Ã°æ ¼ö¼ú(BEVAR) ½ÃÀå Ãß»ê ¹× ¿¹Ãø, 2021³â-2033³â
Á¦5Àå ¼¼°èÀÇ ÈäºÎ ´ëµ¿¸Æ·ù ½ÃÀå ºÎ¹® ºÐ¼®, Á¦Ç°º°, 2021-2033³â
Á¤ÀÇ¿Í ¹üÀ§
Á¦Ç° ½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â ¹× 2033³â
ºÎ¹® ´ë½Ãº¸µå
¼¼°èÀÇ ÈäºÎ ´ëµ¿¸Æ·ù ½ÃÀå(Á¦Ç°º°, 2021³â-2033³â)
´ëµ¿¸Æ ½ºÅÙÆ® ±×·¡ÇÁÆ®
´ëµ¿¸Æ ½ºÅÙÆ® ±×·¡ÇÁÆ® ½ÃÀå Ãß»ê ¹× ¿¹Ãø, 2021³â-2033³â
´ëµ¿¸Æ ¿Ü°ú¿ë ±×·¡ÇÁÆ®
´ëµ¿¸Æ ¿Ü°ú¿ë ±×·¡ÇÁÆ® ½ÃÀå Ãß»ê ¹× ¿¹Ãø, 2021³â-2033³â
´ëµ¿¸Æ ¼öº¹ º¸Á¶ ±â±â
´ëµ¿¸Æ ¼öº¹ º¸Á¶ ±â±â ½ÃÀå Ãß»ê ¹× ¿¹Ãø, 2021³â-2033³â
Á¦6Àå ¼¼°èÀÇ ÈäºÎ ´ëµ¿¸Æ·ù ½ÃÀå ºÎ¹® ºÐ¼®, ÃÖÁ¾ ¿ëµµº°, 2021³â-2033³â
Á¤ÀÇ¿Í ¹üÀ§
ÃÖÁ¾ ¿ëµµ ½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â ¹× 2033³â
ºÎ¹® ´ë½Ãº¸µå
¼¼°èÀÇ ÈäºÎ ´ëµ¿¸Æ·ù ½ÃÀå(ÃÖÁ¾ ¿ëµµº°, 2021³â-2033³â)
º´¿ø
º´¿ø ½ÃÀå Ãß»ê ¹× ¿¹Ãø, 2021³â-2033³â
¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC) ½ÃÀå Ãß»ê ¹× ¿¹Ãø, 2021³â-2033³â
Ŭ¸®´Ð
Ŭ¸®´Ð ½ÃÀå Ãß»ê ¹× ¿¹Ãø, 2021³â-2033³â
Á¦7Àå ÈäºÎ ´ëµ¿¸Æ·ù ½ÃÀå ºÎ¹® ºÐ¼®, Áö¿ªº°, 2021³â-2033³â
Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â ¹× 2033³â
Áö¿ª ½ÃÀå ´ë½Ãº¸µå
Áö¿ª ½ÃÀå ½º³À¼ô
ÈäºÎ ´ëµ¿¸Æ·ù ½ÃÀå Á¡À¯À²(Áö¿ªº°), 2024³â ¹× 2033³â :
ºÏ¹Ì
ºÏ¹ÌÀÇ ÈäºÎ ´ëµ¿¸Æ·ù ½ÃÀå, 2021³â-2033³â
¹Ì±¹
ij³ª´Ù
¸ß½ÃÄÚ
À¯·´
À¯·´ÀÇ ÈäºÎ ´ëµ¿¸Æ·ù ½ÃÀå, 2021³â-2033³â
¿µ±¹
µ¶ÀÏ
ÇÁ¶û½º
ÀÌÅ»¸®¾Æ
½ºÆäÀÎ
³ë¸£¿þÀÌ
½º¿þµ§
µ§¸¶Å©
¾Æ½Ã¾ÆÅÂÆò¾ç
ÀϺ»
Áß±¹
Àεµ
È£ÁÖ
Çѱ¹
ű¹
¶óƾ¾Æ¸Þ¸®Ä«
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
³²¾ÆÇÁ¸®Ä«°øÈ±¹
»ç¿ìµð¾Æ¶óºñ¾Æ
¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
Äí¿þÀÌÆ®
Á¦8Àå °æÀï ±¸µµ
ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷ÀÇ ÃÖ±Ù µ¿Çâ°ú ¿µÇ⠺м®
±â¾÷ ºÐ·ù
±â¾÷ °³¿ä
Medtronic plc
WL Gore &Associates, Inc.
Cook Medical Inc.
Terumo Corporation
MicroPort Scientific Corporation
Boston Scientific Corporation
Artivion Inc.
Cardiatis SA
Endologix Inc.
Braile Biomedica
Lombard Medical
CryoLife, Inc.
LSH
¿µ¹® ¸ñÂ÷
Thoracic Aortic Aneurysm Market Summary
The global thoracic aortic aneurysm market size was estimated at USD 1.65 billion in 2024 and is projected to reach USD 5.04 billion by 2033, growing at a CAGR of 13.36% from 2025 to 2033. This growth is driven by the rising prevalence of hypertension and connective tissue disorders, an increasing aging population, and growing adoption of minimally invasive endovascular procedures.
Technological advancements in stent graft design, improved diagnostic imaging, and early disease detection contribute to market expansion. Supportive reimbursement policies and expanding awareness of thoracic aortic aneurysms among both physicians and patients are further accelerating treatment uptake globally.
The increasing prevalence of hypertension, smoking, and atherosclerosis, which are key risk factors for thoracic aortic aneurysm, is a major driver of market growth. As aging populations grow globally, the incidence of degenerative vascular conditions continues to rise, directly increasing the demand for diagnostic and therapeutic solutions. In March 2025, an article published in Biomedicines analyzed the relationship between atherosclerosis (AS) and aortic aneurysm (AA), including thoracic AA (TAA). It reported comorbidity rates ranging from 18% to 90%, influenced by aneurysm location, age, genetic background, and bicuspid aortic valves.
Technological advancements in endovascular aneurysm repair (TEVAR) have significantly boosted the market by offering minimally invasive alternatives to open surgery. These innovations have led to reduced hospital stays, lower procedural risks, and expanded treatment eligibility for high-risk patients. Device manufacturers are continually developing next-generation stent grafts with enhanced precision, flexibility, and durability, further accelerating their adoption among vascular surgeons worldwide. In May 2025, SHIP International Hospital in Dhaka performed a Thoracic Endovascular Aortic Repair (TEVAR) on a 57-year-old patient with a thoracic aortic aneurysm (TAA), a bulge in the chest portion of the aorta. Referred by a NICVD professor after being denied treatment elsewhere, the patient underwent the minimally invasive procedure with support from an endovascular stent graft vendor.
The growing use of advanced imaging modalities such as CT angiography, MRI, and ultrasound for early and accurate detection of thoracic aortic aneurysms is fueling market growth. National screening programs and increased awareness among both clinicians and patients are contributing to earlier diagnosis and timely intervention. In parallel, artificial intelligence tools and digital health platforms are being integrated into diagnostic pathways, supporting better risk stratification and patient monitoring.
In June 2025, an article published in Nature Communications discussed an AI model that enables opportunistic screening for thoracic aortic aneurysms (TAA) using routine breast MRI scans. The model improved detection rates by 3.5X compared to standard clinical reads. It flagged high-risk patients based on both aortic size and body-size-adjusted indices like AHI and ASI.
Global Thoracic Aortic Aneurysm Market Segmentation
This report forecasts revenue growth and provides at global, regional, and country levels an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global thoracic aortic aneurysm market report based on treatment, product, end use, and region:
Treatment Outlook (Revenue USD Million, 2021 - 2033)
Open Surgical Repair (OSR)
Thoracic Endovascular Aneurysm Repair (TEVAR)
Branched Endovascular Aneurysm Repair (BEVAR)
Hybrid Procedures
Product Outlook (Revenue USD Million, 2021 - 2033)
Aortic Stent Grafts
Aortic Surgical Grafts
Aortic Repair Accessory Devices
End Use Outlook (Revenue USD Million, 2021 - 2033)
Hospitals
Ambulatory Surgery Centers (ASC)
Clinics
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Segment scope
1.1.2. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR's internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.7. Research Assumptions
1.8. List of Secondary Sources
1.9. List of Primary Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Treatment outlook
2.2.2. Product outlook
2.2.3. End use outlook
2.3. Competitive Insights
Chapter 3. Global Thoracic Aortic Aneurysm Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Global Thoracic Aortic Aneurysm: Market Analysis Tools
3.3.1. Industry Analysis - Porter's
3.3.2. PESTLE Analysis
3.4. Treatment Landscape
3.5. Case Study Analysis
Chapter 4. Global Thoracic Aortic Aneurysm Market Segment Analysis, By Treatment, 2021-2033 (USD Million)
4.1. Definition and Scope
4.2. Treatment Market Share Analysis, 2024 & 2033
4.3. Segment Dashboard
4.4. Global Thoracic Aortic Aneurysm Market, by Treatment, 2021 to 2033
4.5. Open Surgical Repair (OSR)
4.5.1. Open surgical repair (OSR) market estimates and forecasts, 2021 to 2033 (USD Million)
4.6. Thoracic Endovascular Aneurysm Repair (TEVAR)
4.6.1. Thoracic endovascular aneurysm repair (TEVAR) market estimates and forecasts, 2021 to 2033 (USD Million)
4.7. Hybrid Procedures
4.7.1. Hybrid procedures market estimates and forecasts, 2021 to 2033 (USD Million)
4.8. Branched Endovascular Aneurysm Repair (BEVAR)
4.8.1. Branched endovascular aneurysm repair (BEVAR) market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 5. Global Thoracic Aortic Aneurysm Market Segment Analysis, By Product, 2021-2033 (USD Million)
5.1. Definition and Scope
5.2. Product Market Share Analysis, 2024 & 2033
5.3. Segment Dashboard
5.4. Global Thoracic Aortic Aneurysm Market, by Product, 2021 to 2033
5.5. Aortic Stent Grafts
5.5.1. Aortic stent grafts market estimates and forecasts, 2021 to 2033 (USD Million)
5.6. Aortic Surgical Grafts
5.6.1. Aortic surgical grafts market estimates and forecasts, 2021 to 2033 (USD Million)
5.7. Aortic Repair Accessory Devices
5.7.1. Aortic repair accessory devices market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 6. Global Thoracic Aortic Aneurysm Market Segment Analysis, By End Use, 2021-2033 (USD Million)
6.1. Definition and Scope
6.2. End Use Market Share Analysis, 2024 & 2033
6.3. Segment Dashboard
6.4. Global Thoracic Aortic Aneurysm Market, by End Use, 2021 to 2033
6.5. Hospitals
6.5.1. Hospitals market estimates and forecasts, 2021 to 2033 (USD Million)
6.6. Ambulatory surgery centers (ASC)
6.6.1. Ambulatory surgery centers (ASC) market estimates and forecasts, 2021 to 2033 (USD Million)
6.7. Clinics
6.7.1. Clinics market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 7. Thoracic Aortic Aneurysm Market Segment Analysis, By Region, 2021- 2033 (USD Million)
7.1. Regional Market Share Analysis, 2024 & 2033
7.2. Regional Market Dashboard
7.3. Regional Market Snapshot
7.4. Thoracic Aortic Aneurysm Market Share by Region, 2024 & 2033:
7.5. North America
7.5.1. North America thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
7.5.2. U.S.
7.5.2.1. Key Country Dynamics
7.5.2.2. Regulatory Scenario
7.5.2.3. Competitive Scenario
7.5.2.4. U.S. thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
7.5.3. Canada
7.5.3.1. Key Country Dynamics
7.5.3.2. Regulatory Scenario
7.5.3.3. Competitive Scenario
7.5.3.4. Canada thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
7.5.4. Mexico
7.5.4.1. Key Country Dynamics
7.5.4.2. Regulatory Scenario
7.5.4.3. Competitive Scenario
7.5.4.4. Mexico thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
7.6. Europe
7.6.1. Europe thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
7.6.2. UK
7.6.2.1. Key Country Dynamics
7.6.2.2. Regulatory Scenario
7.6.2.3. Competitive Scenario
7.6.2.4. UK thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
7.6.3. Germany
7.6.3.1. Key Country Dynamics
7.6.3.2. Regulatory Scenario
7.6.3.3. Competitive Scenario
7.6.3.4. Germany thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
7.6.4. France
7.6.4.1. Key Country Dynamics
7.6.4.2. Regulatory Scenario
7.6.4.3. Competitive Scenario
7.6.4.4. France thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
7.6.5. Italy
7.6.5.1. Key Country Dynamics
7.6.5.2. Regulatory Scenario
7.6.5.3. Competitive Scenario
7.6.5.4. Italy thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
7.6.6. Spain
7.6.6.1. Key Country Dynamics
7.6.6.2. Regulatory Scenario
7.6.6.3. Competitive Scenario
7.6.6.4. Spain thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
7.6.7. Norway
7.6.7.1. Key Country Dynamics
7.6.7.2. Regulatory Scenario
7.6.7.3. Competitive Scenario
7.6.7.4. Norway thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
7.6.8. Sweden
7.6.8.1. Key Country Dynamics
7.6.8.2. Regulatory Scenario
7.6.8.3. Competitive Scenario
7.6.8.4. Sweden thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
7.6.9. Denmark
7.6.9.1. Key Country Dynamics
7.6.9.2. Regulatory Scenario
7.6.9.3. Competitive Scenario
7.6.9.4. Denmark thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
7.7. Asia Pacific
7.7.1. Japan
7.7.1.1. Key Country Dynamics
7.7.1.2. Regulatory Scenario
7.7.1.3. Competitive Scenario
7.7.1.4. Japan thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
7.7.2. China
7.7.2.1. Key Country Dynamics
7.7.2.2. Regulatory Scenario
7.7.2.3. Competitive Scenario
7.7.2.4. China thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
7.7.3. India
7.7.3.1. Key Country Dynamics
7.7.3.2. Regulatory Scenario
7.7.3.3. Competitive Scenario
7.7.3.4. India thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
7.7.4. Australia
7.7.4.1. Key Country Dynamics
7.7.4.2. Regulatory Scenario
7.7.4.3. Competitive Scenario
7.7.4.4. Australia thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
7.7.5. South Korea
7.7.5.1. Key Country Dynamics
7.7.5.2. Regulatory Scenario
7.7.5.3. Competitive Scenario
7.7.5.4. South Korea thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
7.7.6. Thailand
7.7.6.1. Key Country Dynamics
7.7.6.2. Regulatory Scenario
7.7.6.3. Competitive Scenario
7.7.6.4. Thailand thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
7.8. Latin America
7.8.1. Brazil
7.8.1.1. Key Country Dynamics
7.8.1.2. Regulatory Scenario
7.8.1.3. Competitive Scenario
7.8.1.4. Brazil thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
7.8.2. Argentina
7.8.2.1. Key Country Dynamics
7.8.2.2. Regulatory Scenario
7.8.2.3. Competitive Scenario
7.8.2.4. Argentina thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
7.9. MEA
7.9.1. South Africa
7.9.1.1. Key Country Dynamics
7.9.1.2. Regulatory Scenario
7.9.1.3. Competitive Scenario
7.9.1.4. South Africa thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
7.9.2. Saudi Arabia
7.9.2.1. Key Country Dynamics
7.9.2.2. Regulatory Scenario
7.9.2.3. Competitive Scenario
7.9.2.4. Saudi Arabia thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
7.9.3. UAE
7.9.3.1. Key Country Dynamics
7.9.3.2. Regulatory Scenario
7.9.3.3. Competitive Scenario
7.9.3.4. UAE thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
7.9.4. Kuwait
7.9.4.1. Key Country Dynamics
7.9.4.2. Regulatory Scenario
7.9.4.3. Competitive Scenario
7.9.4.4. Kuwait thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company Categorization
8.3. Company Profiles
8.3.1. Medtronic plc
8.3.1.1. Company overview
8.3.1.2. Financial performance
8.3.1.3. Product benchmarking
8.3.1.4. Strategic initiatives
8.3.2. W.L. Gore & Associates, Inc.
8.3.2.1. Company overview
8.3.2.2. Financial performance
8.3.2.3. Product benchmarking
8.3.2.4. Strategic initiatives
8.3.3. Cook Medical Inc.
8.3.3.1. Company overview
8.3.3.2. Financial performance
8.3.3.3. Product benchmarking
8.3.3.4. Strategic initiatives
8.3.4. Terumo Corporation
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. MicroPort Scientific Corporation
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Boston Scientific Corporation
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Artivion Inc.
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Cardiatis S.A.
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Endologix Inc.
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. Braile Biomedica
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Lombard Medical
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
8.3.12. CryoLife, Inc.
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Product benchmarking
8.3.12.4. Strategic initiatives
°ü·ÃÀÚ·á